跳至主要内容
临床试验/NCT07145411
NCT07145411招募中不适用

HPC Offered for PRESERVE Expansion

Ossium Health, Inc.4 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年6月27日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
10
试验地点
4
主要终点
Neutrophil engraftment

研究概览

简要总结

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 12-80 may be eligible* to receive bone marrow for transplantation through the Ossium HOPE Program if:
  • Their treating physician determined they are eligible for allogeneic bone marrow transplant Their treating physician determined that the potential benefit outweighs the potential risks

排除标准

  • 未提供

结局指标

主要结局

Neutrophil engraftment

时间窗: 28 days

1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验